Literature DB >> 8595156

Genes related to growth and invasiveness are repressed by sodium butyrate in ovarian carcinoma cells.

G Krupitza1, S Grill, H Harant, W Hulla, T Szekeres, H Huber, C Dittrich.   

Abstract

Down-regulation of oncogene expression is one of the hallmarks of the process whereby transformed cells are forced into differentiation and/or growth arrest by potent inducers and therefore can represent an interim end point in cancer treatment. The differentiation inducer sodium butyrate (NaB) arrested growth of N.1 ovarian carcinoma cells and repressed expression of cyclin D1/prad1 and the invasiveness-related protease plasminogen activator-urokinase (plau). This was accompanied by the acquisition of a differentiated morphology, all of which characteristics were maintained as long as N.1 cells were exposed to the inducer. In accordance with a differentiated phenotype was the finding that fibronectin expression was increased significantly. Recently, it was shown that NaB represses the transcription factor c-myc by blocking Ca2+ signals and modulating serine threonine kinase activity. We wanted to investigate NaB-mediated interference on signals contributing to the expression on prad1, plau and growth arrest-specific 6 (gas6). Protein kinase A (PKA) inactivation de-repressed prad1 and plau transcript levels. NaB had onlygeneral but no specific influence on PKA-modulated prad1 and plau expression however. Protein kinase C activation up-regulated plau transcript levels, but not that of prad1. Prad1 expression seemed to depend on Ca2+-triggered signals. Constitutive plau expression was insensitive to additional Ca2+-mediated signals, but it became responsive upon NaB treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8595156      PMCID: PMC2074449          DOI: 10.1038/bjc.1996.78

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  Characterization of sublines of HL-60 human leukemia cells resistant to induction of differentiation by butyric acid.

Authors:  S A Fischkoff; M C Hoessly; R M Rossi
Journal:  Leukemia       Date:  1990-04       Impact factor: 11.528

2.  Evidence for a labile intermediate in the butyrate induced reduction of the level of c-myc RNA in SW837 rectal carcinoma cells.

Authors:  K M Herold; P G Rothberg
Journal:  Oncogene       Date:  1988-10       Impact factor: 9.867

3.  Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells.

Authors:  J H Axelrod; R Reich; R Miskin
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

4.  Genes specifically expressed at growth arrest of mammalian cells.

Authors:  C Schneider; R M King; L Philipson
Journal:  Cell       Date:  1988-09-09       Impact factor: 41.582

Review 5.  Fibronectin and its receptors.

Authors:  E Ruoslahti
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

6.  All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results.

Authors:  S Castaigne; C Chomienne; M T Daniel; P Ballerini; R Berger; P Fenaux; L Degos
Journal:  Blood       Date:  1990-11-01       Impact factor: 22.113

7.  Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child.

Authors:  A Novogrodsky; A Dvir; A Ravid; T Shkolnik; K H Stenzel; A L Rubin; R Zaizov
Journal:  Cancer       Date:  1983-01-01       Impact factor: 6.860

8.  Comparative properties of five human ovarian adenocarcinoma cell lines.

Authors:  R N Buick; R Pullano; J M Trent
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

9.  Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma.

Authors:  A Arnold; H G Kim; R D Gaz; R L Eddy; Y Fukushima; M G Byers; T B Shows; H M Kronenberg
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

10.  Macrophage colony-stimulating factor is expressed by an ovarian carcinoma subline and stimulates the c-myc proto-oncogene.

Authors:  G Krupitza; R Fritsche; E Dittrich; H Harant; H Huber; T Grunt; C Dittrich
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

View more
  6 in total

1.  Molecular Events as Targets of Anticancer Drug Therapy.

Authors:  Adorján Aszalós; Sándor Eckhardt
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

2.  Sodium butyrate modulates cell cycle-related proteins in HT29 human colonic adenocarcinoma cells.

Authors:  D Coradini; C Pellizzaro; D Marimpietri; G Abolafio; M G Daidone
Journal:  Cell Prolif       Date:  2000-06       Impact factor: 6.831

3.  Butyrate reduces liver metastasis of rat colon carcinoma cells in vivo and resistance to oxidative stress in vitro.

Authors:  Xiaotong Li; Idun M Mikkelsen; Bente Mortensen; Jan-Olof Winberg; Nils-Erik Huseby
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

4.  Fractionation of an Extract of Pluchea odorata Separates a Property Indicative for the Induction of Cell Plasticity from One That Inhibits a Neoplastic Phenotype.

Authors:  Mareike Seelinger; Ruxandra Popescu; Prapairat Seephonkai; Judith Singhuber; Benedikt Giessrigl; Christine Unger; Sabine Bauer; Karl-Heinz Wagner; Monika Fritzer-Szekeres; Thomas Szekeres; Rene Diaz; Foster M Tut; Richard Frisch; Björn Feistel; Brigitte Kopp; Georg Krupitza
Journal:  Evid Based Complement Alternat Med       Date:  2012-03-13       Impact factor: 2.629

Review 5.  Molecular insights of Gas6/TAM in cancer development and therapy.

Authors:  Guiling Wu; Zhiqiang Ma; Wei Hu; Dongjin Wang; Bing Gong; Chongxi Fan; Shuai Jiang; Tian Li; Jianyuan Gao; Yang Yang
Journal:  Cell Death Dis       Date:  2017-03-23       Impact factor: 8.469

Review 6.  The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling.

Authors:  Adrienn Sipos; Gyula Ujlaki; Edit Mikó; Eszter Maka; Judit Szabó; Karen Uray; Zoárd Krasznai; Péter Bai
Journal:  Mol Med       Date:  2021-04-01       Impact factor: 6.354

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.